![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NICE Approves Three MS Drugs After Price Reductions
NICE Approves Three MS Drugs After Price Reductions
May 16, 2018
The National Institute for Health and Care Excellence recommended three multiple sclerosis treatments — Avonex, Copaxone and Rebif — for approval after the medications experienced price cuts.
Teva’s Copaxone (glatiramer acetate), Biogen’s Avonex and Merck Serono’s Rebif (interferon beta-1a) are now seen as cost-effective options for treating relapsing-remitting MS, NICE said in a draft guidance. Previously, it had only recommended Novartis’ Extavia (interferon beta-1b) as a cost-effective treatment for RRMS.
NICE did not recommend Betaferon — a type of interferon beta-1b produced by Bayer — as a treatment option, citing its lack of cost-effectiveness.
Related Events
Upcoming Events
-
21Oct